期刊文献+

肝细胞癌P-gp定量分析与生物学特性的关系 被引量:2

Relationship between expression of P—glycoprotein and biological character in hepatocellular carcinoma
下载PDF
导出
摘要 研究肝细胞癌 MDR1基因产物 P-gp 的表达及临床意义。方法:应用免疫组化结合图像分析定量测定47例肝癌组织和33例癌旁组织 P-gp 含量,并与肝癌生物学特性比较。结果:肝癌组织和癌旁组织均有 P-gp 表达,且主要位于肝细胞膜上。肝癌组织和癌旁组织 P-gp 含量均高于正常肝组织(P<0.01)。高分化肝癌和肝内复发肝癌 P-gp 含量分别高于低分化肝癌和未复发肝癌(P<0.01),侵袭性肝癌 P-gp 含量也高于非侵袭性肝癌(P<0.05)。结论:P-gp 表达可能成为肝癌预后判断的生物学指标。 To study the clinical significance of the expression of P-glycoprotein(P-gp)in hepatocellular carcinoma(HCC).Methods:Quantitative analysis of P-gp was made by using immunohistochemical method and microimage analysis technique in 47 tumor tissues and 33 tumor-adjacent tissues of the patient with HCC.The biological character was also analyzed.Results:Anti-P-gp immunostaining was observed both in 72 % of cases with tumor tissue and in 66% of cases with adjacent to tumor tissue.When P-gp was detected in HCC,it was mainly localized on the cellular membrane.A significant increase in P-gp level was observed in tumor tissue (P<0.01)and tumor-adjacent tissue(P<0.01)as compared with normal liver tissue.P-gp expression level was significantly higher in HCC of the well differentiated type than in that of poorly differentiated type(P<0.01). HCC with intrahepatic recurrence had a significantly higher P-gp expression level than that without intrahepatic recurrence(P<0.01).P- gp overexpression level correlated well with the invasiveness of HCC(P<0. 05).Conclusion:P-gp expression is Probably a biological marker of Prognostic value to HCC.
出处 《重庆医科大学学报》 CAS CSCD 1998年第4期329-331,共3页 Journal of Chongqing Medical University
基金 本课题受美国中华医学基金会(CMB)资助 编号 90534
关键词 肝细胞癌 肝肿瘤 生物学特性 P-糖蛋白 HCC P-gp Image analysis Immunohistochemistry biological character
  • 相关文献

参考文献2

  • 1申洪.免疫组织化学染色定量方法研究(Ⅲ)[J].中国组织化学与细胞化学杂志,1995,4(1):89-92. 被引量:398
  • 2Sharon Gregorcyk MD,Yuan Kang MD, PhD,D?rthe Brandt MD,Paul Kolm PhD,Gerry Singer MD,Dr. Roger R. Perry MD. p-Glycoprotein expression as a predictor of breast cancer recurrence[J] 1996,Annals of Surgical Oncology(1):8~14

二级参考文献2

共引文献397

同被引文献33

  • 1[2]Zhou XD. Recurrence after resection of alphafetoprotheise positive hepatecellular carcinoma. J Cancer Res olin oncol, 1994, 120: 369~ 373
  • 2[3]Brazeau P, Vale W, Burgns R, et al. Hypothalamic polypeptide that inhibits the secretion of immunereactive pituitary growth hormone.Science, 1973,179: 77 ~ 79
  • 3[4]Longnecker SM. Somsatostain and octreotide: literature review and description of therapeutic activity inpancreatic neoplasia. Drug Intell Clin pharm, 1988,22:99 ~ 106
  • 4[5]Tenkins SA. Somatostain in acute bleeding eso- phageal varices clinical evidence. Drug, 1992,44( suppl, 2): 36
  • 5[6]Ellison EC, Garner wL, Mekhjian HS, et al. Observations on the effect of a somatostain analog the Zollinger - Ellison syndronme, implications forthe treatment of apudomas. Surgery, 1986, 100:437 ~444
  • 6[7]Vinik AL, Tasi S, Moattari AR, et al. Somatostain analogue( SMS201 - 995) in patients with gastrinomas. Surgery, 1988, 104: 834 ~842
  • 7[8]Evers BM, Parekh D, Townttari CM, et al. Somatostain and analogues in the treatment of cancer, A review. Ann Surg, 1991,213:190 ~ 198
  • 8[9]Lamberts SWJ, Vanderlely AJ, Deherder WW, et al. Octerotide N Engl. J Med ,1996,334:246~ 254
  • 9[10]Tahiri- jouti N, Cambillan C, Viguerie N, et al. Characterization of a membrane tyrosine phosphatase in AR42J cell:regulation by somatostain. AMJ Physiol, 1992,262(6) 1007 ~ 1014
  • 10[11]Tortora G. Ptoc Natl Axcad Sci USA, 1991,88(5) :2002 ~ 2015

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部